PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

AGA Expert Review Reframes C difficile Management in IBD

This AGA Clinical Practice Update gives pharmacists 12 actionable Best Practice Advice statements on diagnosing and treating Clostridioides difficile infection in inflammatory bowel disease, emphasizing fidaxomicin, avoidance of metronidazole, and microbiome-based therapy for recurrence.
📅 Journal publication: Jul 2026 (online May 15, 2026) · Last updated: Jul 21, 2026
fidaxomicinvancomycinmetronidazoleClostridioides difficileinflammatory bowel diseaseulcerative colitisCrohn's diseasefecal microbiota transplantationRBLVOSmicrobiome therapyprobioticsoral vancomycin prophylaxisAGA clinical practice updateguideline Infectious Disease / Antimicrobials

Background Information

CDI poses higher risks for IBD patients, complicating management strategies.

Managing Clostridioides difficile infection (CDI) in inflammatory bowel disease (IBD) is crucial due to higher risks and complications compared to non-IBD patients. Best practice advises include using fidaxomicin for CDI, considering microbiome-based therapies for recurrent CDI, and continuing IBD treatment during CDI management. Clear guidance is provided despite lacking formal evidence ratings; practical advice is applicable to real-world clinical decisions. Optimal CDI management in IBD patients requires integrating antibiotic choice with ongoing IBD treatment.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Khanna S, Allegretti JR, Hashash JG, Feuerstadt P

Citation: Khanna S, Allegretti JR, Hashash JG, et al. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review. Gastroenterology. 2026;171(1):184-192. doi:10.1053/j.gastro.2026.03.008

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.